Canada Markets open in 1 hr 9 mins

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
202.24+7.77 (+4.00%)
At close: 04:00PM EDT
205.99 +3.75 (+1.85%)
Pre-Market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close194.47
Open199.10
Bid155.68 x 800
Ask267.86 x 1200
Day's Range198.00 - 205.83
52 Week Range118.18 - 426.56
Volume317,220
Avg. Volume305,691
Market Cap21.485B
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-14.17
Earnings DateAug 07, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est315.21
  • Business Wire

    BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer

    CAMBRIDGE, U.S. & BASEL, Switzerland & BEIJING, August 09, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival (OS) versus sorafenib as a first-line treatment in adult patients with unresectable he

  • Business Wire

    BeiGene Reports Second Quarter 2022 Financial Results

    CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, August 04, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today reported financial results for the second quarter of 2022, recent business highlights, and anticipated upcoming milestones.

  • Zacks

    Why BeiGene (BGNE) Might Surprise This Earnings Season

    BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.